Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
17%
Ph phase_1
1
17%
Ph not_applicable
2
33%
Ph phase_2
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 41 (20.0%)
N/A2 (40.0%)

Trials by Status

completed467%
recruiting117%
withdrawn117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_1

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

NCT04169321
recruitingphase_2

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

NCT05767385
withdrawnnot_applicable

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

NCT04941365
completednot_applicable

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

NCT04552964
completedphase_4

Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders

NCT04045782
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04169321Phase 1

Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

Completed
NCT05767385Phase 2

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Recruiting
NCT04941365Not Applicable

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Withdrawn
NCT04552964Not Applicable

Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

Completed
NCT04045782Phase 4

Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders

Completed
NCT02702297

Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes

Completed

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6